MeiraGTx Holdings plc Ordinary Shares (MGTX) Stock Price

MGTXStock

$14.92+89.40%52W

Market Cap$1.43B

P/E—

PEG Ratio—

Div yield—

Beta1.33

MGTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)86.22%

Price vs S&P 500 (4W)22.41%

VGM Score56.36

Book Value / Share (Quarterly)$0.04

P/TBV (Annual)7.10x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)72.27%

Cash Flow / Share (Quarterly)$0.05

Price vs S&P 500 (YTD)74.58%

Gross Margin (TTM)95.41%

Net Profit Margin (TTM)-151.12%

EPS (TTM)$-1.49

10-Day Avg Trading Volume0.72M

EPS Excl Extra (TTM)$-1.49

Revenue Growth (5Y)39.22%

EPS (Annual)$-1.42

ROI (Annual)-104.78%

Gross Margin (Annual)94.05%

Net Profit Margin (5Y Avg)-441.82%

Cash / Share (Quarterly)$0.88

Revenue Growth QoQ (YoY)-84.79%

ROA (Last FY)-46.72%

Revenue Growth TTM (YoY)131.13%

EBITD / Share (TTM)$-1.14

ROE (5Y Avg)-91.21%

Operating Margin (TTM)-131.89%

Cash Flow / Share (Annual)$-0.62

P/B Ratio416.43x

P/B Ratio (Quarterly)177.20x

Net Income / Employee (Annual)$-285,500

EV / Revenue (TTM)15.49x

Net Interest Coverage (TTM)-13.13x

ROA (TTM)-54.96%

EPS Incl Extra (Annual)$-1.42

Current Ratio (Annual)0.75x

Quick Ratio (Quarterly)0.51x

3-Month Avg Trading Volume0.89M

52-Week Price Return89.40%

Revenue / Employee (TTM)$199,400

Tangible BV / Share (Quarterly)$0.03

P/S Ratio (Annual)15.14x

Asset Turnover (Annual)0.33x

52-Week High$15.35

Operating Margin (5Y Avg)-505.07%

EPS Excl Extra (Annual)$-1.42

CapEx CAGR (5Y)-30.17%

Tangible BV CAGR (5Y)-18.82%

26-Week Price Return97.47%

Quick Ratio (Annual)0.70x

13-Week Price Return56.27%

Total Debt / Equity (Annual)1.08x

Current Ratio (Quarterly)0.55x

Enterprise Value$1.24B

Revenue / Share Growth (5Y)19.66%

Asset Turnover (TTM)0.36x

Book Value / Share Growth (5Y)-30.10%

Revenue / Employee (Annual)$203,500

Pretax Margin (Annual)-140.31%

Cash / Share (Annual)$0.81

3-Month Return Std Dev60.20%

Net Income / Employee (TTM)$-301,300

ROE (Last FY)-217.89%

Net Interest Coverage (Annual)-2.85x

EPS Basic Excl Extra (Annual)$-1.42

P/FCF (TTM)19.83x

Receivables Turnover (TTM)37.38x

EV / Free Cash Flow (TTM)297.42x

Total Debt / Equity (Quarterly)24.92x

EPS Incl Extra (TTM)$-1.49

Receivables Turnover (Annual)34.95x

ROI (TTM)-127.78%

P/S Ratio (TTM)15.45x

Pretax Margin (5Y Avg)-441.82%

Revenue / Share (Annual)$1.01

Tangible BV / Share (Annual)$0.85

Forward P/E47.85x

Price vs S&P 500 (52W)71.09%

Year-to-Date Return86.54%

5-Day Price Return6.77%

EPS Normalized (Annual)$-1.42

ROA (5Y Avg)-38.56%

Net Profit Margin (Annual)-140.31%

Month-to-Date Return25.78%

Cash Flow / Share (TTM)$-2.29

EBITD / Share (Annual)$-1.31

Operating Margin (Annual)-130.20%

LT Debt / Equity (Annual)1.08x

P/CF (TTM)148.89x

ROI (5Y Avg)-56.13%

LT Debt / Equity (Quarterly)24.92x

EPS Basic Excl Extra (TTM)$-1.49

P/TBV (Quarterly)236.48x

P/B Ratio (Annual)7.02x

Inventory Turnover (TTM)25.16x

Pretax Margin (TTM)-151.12%

Book Value / Share (Annual)$0.87

Price vs S&P 500 (13W)53.48%

Beta1.33x

P/FCF (Annual)111.45x

Revenue / Share (TTM)$0.98

ROE (TTM)-315.61%

52-Week Low$6.62

vGradeD

gGradeC

mGradeA

vgmGradeC

MGTX Earnings Surprise History

Q2 25-0.48est. -0.47

Q3 25-0.62est. -0.49

Q4 250.19est. -0.62

Q1 26-0.57est. -0.45

Q2 262.52est. -0.42

MGTX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.21

4.23

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	C	$14.56

About MeiraGTx Holdings plc Ordinary Shares

MeiraGTx Holdings is a clinical-stage gene therapy company developing AAV-based treatments for genetic disorders affecting the eye, salivary gland, and central nervous system. Its pipeline includes programs such as AAV-CNGB3 and AAV-RPGR targeting inherited retinal dystrophies and other rare genetic conditions. The company operates across the United States, United Kingdom, and European Union.